Compare Live Nation Entertainment, Inc. (LYV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Novartis AG — how do they compare? Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 6.9× Live Nation Entertainment, Inc.'s market cap, and Novartis AG pays a 3.07% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | NVS | |
|---|---|---|
Market Cap | $42.71B | $295.37B |
Sector | Industrials | Health |
52-Week High | $186.59 | $168.62 |
52-Week Low | $125.61 | $119.31 |
Enterprise Value | $44.92B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
